Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41

ConclusionsAlthough pCR, RFI, and OS were numerically better with the dual combination and less with L, the differences were not statistically significant. However, achievement of pCR again correlated with improved outcomes, especially remarkable in the ER-negative subset.Clinical trials registrationNCT00486668
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research